Advancing Treatment of

Bladder Cancer

Advancing Treatment of Bladder Cancer

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

InforMEDical Communications, Inc. • 83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com

References

  • 1.  American Cancer Society: Cancer Facts and Figures, 2005. Available at: http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. Accessed March 10, 2005.
  • 2.  Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165:1111-1116.
  • 3.  Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002; 41:440-448.
  • 4.  Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
  • 5.  Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer—Genitourinary Group. J Urol 1992; 147:606-608.
  • 6.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-540.
  • 8.  Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2901-2907.
  • 9.  Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
  • 10.  Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155:1903-1906.
  • 11.  Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153:964-973.
  • 12.  Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45:297-303.
  • 13.  Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer — Nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36:419-425.
  • 14.  Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16:3576-3583.
  • 15.  Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67:608-615.
  • 16.  Hall R, Group MACB. Updated results of a randomized trial of neoadjuvant cisplatin (C), methotrexate (M), and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002; 21:710a.
  • 17.  Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-464; discussion 464-457.
  • 18.  Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148:302-306; discussion 306-307.
  • 19.  Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000; 11:851-856.
  • 20.  Montie JE, Bahnson RR, Cohen SM, et al. The NCCN Bladder Cancer Clinical Practice Guidelines in Oncology. JNCCN 2005; 3:4-34.
  • 21.  Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996; 14:86-95.
  • 22.  Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.
  • 23.  Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62-67; discussion 67-68.
  • 24.  Sternberg CN, Pansadoro V, Calabro F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97:1644-1652.
  • 25.  Scher HI, Kantoff PW. Chemotherapy for muscle-infiltrating bladder cancer. Hematol Oncol Clin North Am 1992; 6:169-178.
  • 33.  Jahnson S, Karlsson MG. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy. J Urol 1998; 160:1291-1296.
  • 34.  Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85:53-59.
  • 35.  Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84:1251-1256.
  • 36.  Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84:1256-1261.
  • 37.  Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer: therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46(Suppl):S85-S104.
  • 38.  Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003; 97:2064-2075.
  • 39.  Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-1264.
  • 40.  Fleshner N, Kapusta L, Ezer D, et al. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000; 164:1177-1182.
  • 41.  Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7:1957-1962.
  • 42.  Jimenez RE, Hussain M, Bianco FJ, Jr., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7:2440-2447.
  • 43.  Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
  • 44.  Hussain M, Smith DC, Vaishampayan U, et al. Trastuzumab (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer and overexpression of HER-2. (NCI study #198). Proc Am Soc Clin Oncol 2003; 22:1569a.
  • 45.  Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130:1083‐1086.
  • 46.  Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158:62-67.
  • 47.  Schmitz-Dräger BJ, Fradet Y, Grossman HB. Bladder cancer markers in patient management: the current perspective. World J Urol. 2008; 26(1):1-3.
  • 48.  Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171(6 pt 1): 2186-2190.
  • 49.  Rajala P, Kaasinen E, Raitanen M, et al. Perioperative single dose instillation of epirubicin or interferon-o after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-FinnBladder III longterm results. J Urol 2002; 168:981‐985.
  • 50.  Lamm DL, Herr H, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998; 4:130‐135.
  • 51.  Abel PD. Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993;72:135‐142.
  • 52.  Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007; 52(4):1123-1129.
  • 53.  Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;. 163:1124‐1129.
  • 54.  Divrik RT, Yildirim U, Zorlu F, et al. the effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin" a prospective, randomized clinical trial. J Urol 2006; 175(5):1641-1644.
  • 55.  Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol. 2006, 176(2):482-485.
  • 56.  Sylvesteer RJ, Adrian PM, van der Meijden J, et al. BCG versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;. 175:86‐92.
  • 57.  Sylvester RJ, Van der Meijden AP, Lamm DL. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;. 168:1964-1970.
  • 58.  Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135-138.
  • 59.  Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005-4013.
  • 60.  Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163(3):761-767.
  • 61.  Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20:3193‐3198.
  • 62.  O'Donnell MA, Lilli K, Leopold C. National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group: interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172:888‐893.
  • 63.  Rintala E, Jauhiainen K, Rajala P, et al. Alternating mitomycin-C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol 1995; 154:2050‐2053.
  • 64.  Rintala E, Jauhiainen K, Kaasinen E, et al. Alternating mitomycinC and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol 1996; 156:56‐59.
  • 65.  Witjes JA, Caris CT, Mungan NA, et al. Results of a randomised phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998; 160:1668‐1671.
  • 66.  Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003; 43:637‐645.
  • 67.  Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7:43‐51.
  • 68.  Benedict WF, Tao Z, Kim CS, et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10:525‐532.
  • 69.  Gomella LG, Mastrangelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001; 166:1291‐1295.

< < PREVIOUS